Remove Engineering Remove Marketing Remove RNA
article thumbnail

New tRNA tech aims to rewrite rare disease treatment

Drug Target Review

One company leading the charge in this revolution is Alltrna , whose pioneering work in engineered transfer RNA (tRNA) therapeutics is offering new hope for patients with rare genetic diseases. we are first focused on engineering tRNAs to restore protein production in diseases caused by premature termination codons.

Disease 80
article thumbnail

Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management

LifeSciVC

Founding Vision: Harnessing RNA Editing for Transformative Medicine Korro Bio’s story began in 2018, co-founded by a remarkable group: Jean-François Formela, M.D. Academic specializing in RNA editing). The ability of modifying RNA enabled us to sidestep many of the potential risks associated with permanent DNA editing.

RNA 68
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BioDAOs are Community-Owned Research Translation Engines, Not Investment DAOs

Molecule Blog

Moving research from concept to market is like conducting a symphony — there are numerous players and stakeholders, each bringing their unique expertise to work in harmony and advance a project. If approved, the company can then market and distribute the therapeutic. How do BioDAOs differ from investment DAOs?

article thumbnail

Women in STEM with Juliet Williams

Drug Target Review

This laid the groundwork for my career in drug discovery using novel modalities like small molecule inhibitors, antibodies, RNA interference (RNAi) and, currently, small molecule protein degraders – which are opportunities to change how we think about medicines. I’ve already had a number of ‘rocking chair’ moments in my career.

article thumbnail

Targeted drug treatment leads tumor cells to imitate viral infection

Broad Institute

Drugs that block mutated IDH1 (mIDH1) have recently come onto the market and effectively slow tumor growth, but the exact mechanism at work to stall tumors is still unclear. Reporting in Science , researchers at Massachusetts General Hospital and the Broad Institute of MIT and Harvard have made a surprising discovery about these drugs.

article thumbnail

Biopharma Money on the Move: December 2 – 8

The Pharma Data

The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. The engineered cells are protected by Sigilon’s Afibromer biomaterials matrix, which shields them from immune rejection and fibrosis. SciNeuro Pharmaceuticals .

RNA 52
article thumbnail

Women in Stem with Dr Emily Leproust

Drug Target Review

Because I was put into the highest tier, I was automatically mapped to the engineering track. Now, ten years later, I’m still CEO, we’ve raised over $1 billion and we’re on a path to profitability with no plans to go back to the capital markets. I was very good at math, which at the time in France directed me towards STEM studies.

DNA 116